- Condition: Knee Osteoarthritis
Interventions: Drug: SAR113945; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Neoplasm Malignant
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: liraglutide
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Mitoxantrone; Drug: Prednisone; Drug: Pegfilgrastim
Sponsors: University of California, San Francisco; Andrea Harzstark; Sanofi-Aventis
Not yet recruiting - verified May 2012 - Condition: Neoplasm Malignant
Interventions: Drug: SAR245408; Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified April 2012 - Condition: Venous Thromboembolic Diseases
Interventions: Drug: Bemiparin; Drug: Enoxaparin; Other: control group
Sponsors: Hawler Medical University; Hawler Medical University
Recruiting - verified May 2012 - Condition: Osteoarthritis
Intervention: Drug: Hylan G-F 20 (Synvisc)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Infertility
Interventions: Drug: Prednisolone and Heparin during COH for IVF; Drug: COH for IVF
Sponsors: National and Kapodistrian University of Athens; National and Kapodistrian University of Athens
Recruiting - verified May 2012 - Condition: Solid Tumor
Interventions: Drug: SAR302503; Drug: omeprazol; Drug: metoprolol; Drug: midazolam
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified April 2012 - Condition: Gastric Adenocarcinoma
Interventions: Drug: Oxaliplatin+S-1; Drug: Adjuvant Oxaliplatin/S-1（SOX）
Sponsors: Chinese PLA General Hospital; Lin Chen
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Physiology of Microvascular Skin
Interventions: Drug: acetylsalicilic acids (Aspirin); Drug: Placebo
Sponsors: University Hospital, Angers; University Hospital, Angers
Recruiting - verified April 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: CABAZITAXEL (XRP6258); Drug: DOCETAXEL (XRP6976)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified April 2012 - Condition: Thrombosis Prophylaxis (Risk of Thrombosis Due to CVL)
Intervention: Drug: Semuloparin Sodium (AVE5026)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Hypercholesterolemia
Intervention: Drug: REGN727 (SAR236553)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Enrolling by invitation - verified April 2012 - Condition: Influenza
Interventions: Biological: Influenza vaccine (split virion), inactivated; Biological: Influenza vaccine (split virion), inactivated; Biological: Influenza vaccine (split virion), inactivated
Sponsors: Hualan Biological Engineering, Inc.; Hualan Biological Engineering, Inc.
Completed - verified March 2012 - Condition: Influenza
Interventions: Biological: Inactivated Influenza Vaccine (Split virion); Biological: Inactivated Influenza Vaccine
Sponsors: Hualan Biological Engineering, Inc.; Hualan Biological Engineering, Inc.
Completed - verified April 2012 - Condition: Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
Interventions: Drug: hydroxychloroquine (Z0188); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Dengue; Dengue Fever; Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus; Biological: Placebo: NaCl 0.9% solution
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Atopic Dermatitis
Interventions: Drug: REGN668; Other: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified March 2012 - Condition: Smallpox
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified February 2012 - Condition: Healthy
Interventions: Biological: SAR231893 (REGN668) DP1; Biological: SAR231893 (REGN668) DP2
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: weekly cabazitaxel
Sponsors: Karolinska University Hospital; Jeffrey Yachnin M.D., PhD.; Sanofi-Aventis
Not yet recruiting - verified March 2012 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: SAR156597; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Advanced Gastric Carcinoma
Interventions: Drug: Oxaliplatin capecitabine; Drug: Oxaliplatin S-1; Drug: Oxaliplatin S-1
Sponsors: Peking University; Peking University; Sanofi-Aventis; Taiho Pharmaceutical Co., Ltd.
Not yet recruiting - verified February 2012 - Condition: Neoplasm Malignant
Intervention: Drug: Cabazitaxel XRP6258
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Androgen Ablation; Drug: Cabazitaxel; Drug: Salvage Therapy; Drug: Neoadjuvant Treatment - Hormonal Therapy; Drug: Neoadjuvant Treatment - Cabazitaxel
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Meningitis; Meningococcal Meningitis; Meningococcal Infections
Intervention: Biological: Meningococcal polysaccharide diphtheria toxoid conjugate
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Lixisenatide (AVE0010)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin + Glucophage tablet fasted; Drug: Dapagliflozin/metformin IR FDC tablet fasted; Drug: Dapagliflozin + Glucophage tablet fed; Drug: Dapagliflozin/metformin IR FDC tablet fed
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Withdrawn - verified April 2012 - Condition: Gastric Cancer
Interventions: Drug: DOCETAXEL (XRP6976); Drug: OXALIPLATIN (SR96669); Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + CDHP (Gemeracil) + Oxo (Oteracil)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi-Aventis; Amylin Pharmaceuticals, Inc.; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Not yet recruiting - verified February 2012 - Condition: Hypercholesterolemia
Interventions: Drug: placebo; Drug: SAR236553(REGN727)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Atrial Fibrillation; Medication Adherence
Intervention: Other: Education and telephone follow-up
Sponsors: Creighton University; Creighton University; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Abiraterone acetate
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee OsteoarthritisCondition: Knee Osteoarthritis
Interventions: Drug: placebo; Drug: SAR113945
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: REGN1033(SAR391786); Drug: REGN1033(SAR391786); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Diabetes Mellitus
Interventions: Other: Sugar infusion; Drug: insulin infusion
Sponsors: IKFE Institute for Clinical Research and Development; IKFE Institute for Clinical Research and Development; Sanofi-Synthelabo
Completed - verified December 2011 - Condition: Small Cell Lung Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Prednisone; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Not yet recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Gastric Cancer
Intervention: Drug: cabazitaxel XRP6258
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo; Drug: Teriflunomide (HMR1726)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified December 2011 - Conditions: Diphtheria; Tetanus; Pertussis; Polio
Intervention: Biological: DTacP IPV//PRP~T combined vaccine: PENTAXIM®
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified May 2012 - Conditions: Dengue; Dengue Fever; Dengue Hemorrhagic Fever; Yellow Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus; Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus; Biological: Yellow Fever + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus; Biological: Yellow Fever
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine HOE901; Drug: Insulin glargine - New formulation HOE901
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified April 2012 - Condition: Chronic Kidney Disease
Intervention: Drug: SAR407899A
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Infertility
Intervention: Drug: 17beta-estradiol
Sponsors: Gemer; Gemer
Completed - verified December 2011 - Condition: Healthy
Interventions: Drug: REGN668: Injection Rate 1; Drug: REGN668: Injection Rate 2
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Completed - verified March 2012 - Condition: Influenza
Interventions: Biological: Quadrivalent Influenza Vaccine (split virion, inactivated); Biological: Quadrivalent Influenza Vaccine (split virion, inactivated); Biological: Quadrivalent Influenza Vaccine (split virion, inactivated); Biological: 2011 to 2012 Trivalent Influenza Vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: SAR228810; Drug: SAR228810
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: SAR3419
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Dengue; Dengue Fever; Dengue Hemorrhagic Fever
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified November 2011 - Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: SAR3419; Drug: rituximab
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Asymptotic Venous Thrombosis
Intervention: Drug: Enoxaparin
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children
Recruiting - verified November 2011 - Conditions: Polio; Poliomyelitis
Interventions: Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Biological: Live oral poliovirus type 1, 2 and 3
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine /lixisenatide fixed combination (HOE901/AVE0010); Drug: Insulin glargine (HOE901)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes
Intervention: Drug: Glargine
Sponsors: Joslin Diabetes Center; Joslin Diabetes Center; Sanofi-Aventis
Recruiting - verified November 2011 - Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Knee Osteoarthritis
Interventions: Drug: SAR113945; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: INSULIN GLARGINE HOE 901
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: docetaxel and epirubicin; Drug: docetaxel and epirubicin plus endostatin
Sponsors: Xijing Hospital; Xijing Hospital
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: GLIMEPIRIDE; Drug: METFORMIN
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Nephropathy
Intervention: Drug: Pentoxifylline
Sponsors: Shiraz University of Medical Sciences; Shiraz University of Medical Sciences
Recruiting - verified November 2011 - Conditions: Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabazitaxel; Drug: prednisone; Drug: octreotide pamoate; Other: questionnaire administration; Drug: octreotide acetate
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Sanofi-Aventis
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Glimepiride and Metformin hydrochloride combination (HOE490); Drug: Glimepiride (HOE490)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Advanced Ovarian Cancer
Interventions: Drug: Neoadjuvant chemotherapy; Drug: Carboplatin
Sponsors: Asan Medical Center; Asan Medical Center; Sanofi-Aventis
Recruiting - verified October 2011 - Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type b (Hib); Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA); Biological: DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Diabetes Mellitus, Type 2
Intervention: Behavioral: a specific frequency of SMBG
Sponsors: Medical Research Foundation, The Netherlands; Medical Research Foundation, The Netherlands; Sanofi-Aventis
Recruiting - verified October 2011 - Condition: Neoplasm Malignant
Interventions: Drug: Iniparib (SAR240550-BSI-201); Drug: Gemcitabine; Drug: Carboplatin; Drug: Placlitaxel; Drug: Pegylated liposomal doxorubicin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Hypercholesterolaemia
Intervention: Drug: SAR236553/REGN727
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified February 2012 - Condition: Hypercholesterolaemia
Interventions: Drug: SAR236553/REGN727; Drug: SAR236553/REGN727
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified February 2012 - Conditions: Pneumonia; Pneumococcal Infections; Streptococcus Pneumoniae Infections
Interventions: Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine Low Dose (Formulation 2); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine Middle Dose (Formulation 3); Biological: Pneumococcal Vaccine Middle Dose (Formulation 4); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Malaria
Interventions: Drug: SAR97276A; Drug: arthemeter + lumefantrine (ACTs)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Terminated - verified February 2012 - Conditions: Diphtheria; Tetanus; Whooping Cough; Hepatitis B; Poliomyelitis
Interventions: Biological: DTaP-IPV-Hep B-PRP-T combined vaccine + Pneumococcal polysaccharide; Biological: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide; Biological: DTaP-IPV-Hep B-PRP-T + Pneumococcal polysaccharide vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Enrolling by invitation - verified March 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Solid Tumors
Interventions: Drug: MM-121 (SAR256212) plus Gemcitabine; Drug: MM-121 (SAR256212) plus Carboplatin; Drug: MM-121 (SAR256212) plus Pemetrexed; Drug: MM-121 (SAR256212) plus Cabazitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis US, Inc.
Recruiting - verified January 2012 - Conditions: Pneumococcal Infections; Pneumococcal Pneumonia
Interventions: Biological: Pneumococcal Vaccine; Biological: Pneumococcal Vaccine; Biological: Pneumococcal Vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified September 2011 - Conditions: Pneumococcal Infections; Streptococcus Pneumoniae Infections; Pneumococcal Pneumonia
Interventions: Biological: Pneumococcal Vaccine Formulation 1; Biological: Pneumococcal Vaccine Formulation 2; Biological: Pneumococcal Vaccine Formulation 3; Biological: Pneumococcal Vaccine Formulation 4; Biological: Pneumococcal Vaccine Formulation 5; Biological: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified September 2011 - Conditions: Pneumococcal Infections; Streptococcus Pneumoniae Infections; Pneumococcal Pneumonia
Interventions: Biological: Pneumococcal vaccine Formulation 1; Biological: Pneumococcal vaccine Formulation 2; Biological: Pneumococcal vaccine Formulation 3; Biological: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified September 2011 - Condition: Hypercholesterolaemia
Interventions: Drug: SAR236553/REGN727 (Solution); Drug: SAR236553/REGN727 (Lyophilized formulation); Drug: Placebo (Solution); Drug: Placebo (Lyophilized formulation)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified February 2012 - Condition: Hypercholesterolaemia
Intervention: Drug: SAR236553/REGN727
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified February 2012 - Condition: Acute Lymphocytic Leukaemia
Intervention: Drug: SAR3419
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Meningitis; Meningococcal Infection
Intervention: Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified December 2011 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Early combination therapy; Drug: Delayed combination therapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011 - Conditions: Tetanus; Diphtheria; Pertussis; Whooping Cough
Interventions: Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological: Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Enrolling by invitation - verified January 2012 - Conditions: Diphtheria; Tetanus; Pertussis; Poliomyelitis
Intervention: Biological: TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Biological: ALVAC-HIV; Biological: AIDSVAX B/E; Biological: ALVAC-HIV Placebo; Biological: AIDSVAX B/E Placebo
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Enrolling by invitation - verified March 2012 - Condition: Solid Tumor Cancers
Interventions: Drug: MM-121 (SAR256212); Drug: SAR245408
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Merrimack Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pain
Interventions: Drug: SSR411298; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Conditions: Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC
Interventions: Drug: Cabazitaxel-XRP6258; Drug: Cabazitaxel-XRP6258
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Adefovir Dipivoxil and polyene phosphatidylcholine; Drug: Adefovir Dipivoxil
Sponsors: Capital Medical University; Jun Cheng; Sanofi-Aventis; Fujian Cosunter Pharmaceutical Co. Ltd
Not yet recruiting - verified September 2011 - Conditions: Dengue; Dengue Hemorrhagic Fever; Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus; Biological: Yellow fever vaccine; Biological: Measles, mumps, and rubella vaccine; Biological: Pneumococcal Conjugated Vaccine; Biological: Hepatitis A Pediatric Vaccine; Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine; Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus; Biological: Yellow Fever Vaccine; Biological: Placebo (NaCl); Biological: Measles, mumps, and rubella vaccine; Biological: Pneumococcal Conjugated Vaccine; Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation; Biological: Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified October 2011 - Condition: Pain
Interventions: Drug: IBUPROFEN + CAFFEINE; Drug: IBUPROFEN
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified February 2012 - Conditions: Meningococcal Disease; Meningitis
Interventions: Biological: Meningococcal (Groups A and C) Polysaccharide Vaccine; Biological: Meningococcal (Groups A and C) Polysaccharide Vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Condition: Influenza
Interventions: Biological: High Dose Trivalent Inactivated Influenza Vaccine; Biological: Trivalent Inactivated Influenza Vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified February 2012 - Condition: Urothelial Carcinoma
Interventions: Drug: Cabazitaxel; Drug: Neulasta; Procedure: CT Scan; Biological: Blood Draw
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified April 2012 - Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Anti-Androgen Therapy: Bicalutamide; Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Sanofi-Aventis
Recruiting - verified January 2012 - Conditions: Dengue; Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus; Biological: DTaP IPV//Hib vaccine; Biological: Placebo; Biological: Measles, mumps, and rubella vaccine; Biological: Pneumococcal vaccine; Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus; Biological: DTaP IPV//Hib vaccine; Biological: Placebo; Biological: Measles, mumps, and rubella vaccine; Biological: Pneumococcal vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012 - Conditions: Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Lymphoma
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Tuberculosis
Intervention: Drug: Higher-Dose Rifampin
Sponsors: Harvard University Faculty of Medicine; Harvard University Faculty of Medicine; National Institute of Allergy and Infectious Diseases (NIAID); Sanofi-Aventis; Harvard School of Public Health; Brigham and Women's Hospital; University of Liverpool; Universidade Federal do Espírito Santo; Socios En Salud Sucursal Perú; St George's, University of London; University of Florida
Not yet recruiting - verified August 2011 - Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Intervention: Drug: Liraglutide-metformin vs insulin-metformin
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Diabete Quebec; Radiological Society of North America Research and Education Foundation; Canadian Heads of Academic Radiology-GE Healthcare Development Award
Recruiting - verified July 2011 - Condition: Multiple Sclerosis
Interventions: Drug: teriflunomide (HMR1726); Drug: teriflunomide (HMR1726)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified February 2012 - Conditions: Japanese Encephalitis; Japanese Encephalitis Virus Disease
Interventions: Biological: Live attenuated Japanese encephalitis chimeric virus vaccine; Biological: Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified January 2012 - Conditions: Myocarditis; Pericarditis
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Infection Prophylaxis
Interventions: Drug: SAR279356; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Malignant Solid Tumors
Intervention: Drug: SAR125844
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Neoplasm Malignant
Intervention: Drug: SAR245408
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Poliomyelitis; Polio
Intervention: Biological: Inactive Poliovirus Vaccine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified April 2012 - Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related SurgeryCondition: Thrombosis, Venous
Interventions: Drug: dalteparin; Drug: enoxaparin; Drug: fondaparinux; Drug: unfractionated heparin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Malaria
Interventions: Drug: ARTESUNATE + AMODIAQUINE; Drug: Chloroquine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel 10mg/m2; Drug: Cabazitaxel 12.5mg/m2; Drug: Experimental: Cabazitaxel 15mg/m2; Drug: Experimental: Cabazitaxel 17.5mg/m2; Drug: Cabazitaxel 20mg/m2
Sponsors: Mount Sinai School of Medicine; Krzysztof Misiukiewicz; Sanofi-Aventis; Mount Sinai School of Medicine
Recruiting - verified November 2011 - Conditions: Dengue Fever; Dengue Hemorrhagic Fever; Dengue
Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Biological: Placebo: NaCl 0.9% solution
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified March 2012 - Conditions: Dengue; Dengue Fever; Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Biological: Placebo: NaCl 0.9%
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified December 2011 - Safety and Tolerability of REGN668 (SAR231893) in Patients With Moderate to Severe Atopic DermatitisCondition: Atopic Dermatitis
Interventions: Biological: REGN668 (SAR231893); Biological: REGN668 (SAR231893)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Completed - verified April 2012 - Condition: NSCLC
Interventions: Drug: Bevacizumab; Drug: Cisplatin; Drug: Docetaxel
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie; Sanofi-Aventis; Roche Pharma AG
Recruiting - verified June 2011
 |
Sanofi-Aventis - Database of Clinical Trials by Pharmaceutical Companies |
